SCHEMBL21995371

SCHEMBL21995371

CC(O[Si](C)(C)C(C)(C)C)C(Nc1c(N)cnc2ccccc12)C(C)(C)O

nearest known ligand 0.41

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 1/20 0.36
TNF P01375 3/20 0.31
PDE4B Q07343 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21995369 1.00 LRRK2 (0.36) LRRK2TNFPDE4B
SCHEMBL21995574 0.85 SMN1; SMN2 (0.34) LRRK2
SCHEMBL21995573 0.85 SMN1; SMN2 (0.34) LRRK2
SCHEMBL21995058 0.79 LRRK2 (0.44) LRRK2TNFPDE4B
SCHEMBL21995056 0.79 LRRK2 (0.44) LRRK2TNFPDE4B
SCHEMBL1774021 0.75 LRRK2 (0.37) LRRK2PDE4B
SCHEMBL22749275 0.75 LRRK2 (0.40) LRRK2TNF
SCHEMBL22749276 0.75 LRRK2 (0.40) LRRK2TNF
SCHEMBL22749313 0.73 LRRK2 (0.46) LRRK2
SCHEMBL22749310 0.73 LRRK2 (0.46) LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12540137-B2 N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2026-02-03 US disclosed
US-20240300947-A1 N-1 Branched Alkyl Ether Substituted Imidazo[4,5-c]Quinoline Compounds, Compositions, and Methods SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2024-09-12 US disclosed
US-12024514-B2 N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2024-07-02 US disclosed
EP-3887369-B1 N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2024-05-08 EP disclosed
US-20210323962-A1 N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2021-10-21 US disclosed
EP-3887369-A1 N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS 3M Innovative Properties Company (US) 2021-10-06 EP disclosed
CN-113166143-A N-1 branched alkyl ether substituted imidazo [4,5-c ] quinoline compounds, compositions, and methods 3M创新有限公司 2021-07-23 CN disclosed
WO-2020109898-A1 N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2020-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12540137-B2 N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods IRF3, IFNAR1, IFNG LRRK2 1295/4885TNF 114/4885PDE4B 3929/4885
US-20240300947-A1 N-1 Branched Alkyl Ether Substituted Imidazo[4,5-c]Quinoline Compounds, Compositions, and Methods IFNG, IFNAR1, IRF3 LRRK2 3506/4885TNF 185/4885PDE4B 2696/4885
US-20210323962-A1 N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS IFNG, IFNAR1, IRF3 LRRK2 2912/4885TNF 121/4885PDE4B 2886/4885
US-12024514-B2 N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods IFNG, IFNAR1, IRF3 LRRK2 2912/4885TNF 121/4885PDE4B 2886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.